Role of oxidative and nitrosative stress in cisplatin cardiotoxicity Entry Cisplatin, bladder, head and neck, solid organ such as lung, testis and ovary used in the treatment of tumors It is an effective chemotherapeutic.1 Major side effects effects include nephrotoxicity, neurotoxicity and myelosuppression. Although these side effects use and anticancer efficacy the most serious and dose-limiting Although nephrotoxicity2, in recent years during the use of cisplatin in studies and development of cardiotoxicity raised as an important problem has arrived. 3-5 As a primary treatment for cisplatin A major problem of acute cardiotoxicity as well as chemotherapy clinical signs that occur during toxic cardiac effects results appear years later. 6 20 from cisplatin treatment still detectable in circulation, even after years level of cisplatin; it's late considered responsible for the complication has been done. 7. Therefore also possibility of causing cardiotoxicity in the use of drugs with high prevent cardiotoxicity as early as possible. It is important to determine. Secondary to cisplatin chemotherapy observable cardiac pathologies failure, angina, acute myocardial infarction, thromboembolic events, hypertension, hypotension, myocarditis, pericarditis, It can be considered as congestive cardiomyopathy. As the cause of these pathologies; vascular endothelial damage, coronary vasospasm, oxidative and nitrosative stress in platelet functions. disruption, platelet apoptosis, platelet aggregation, fluid electrolyte imbalance, ventricular repolarization, mitochondrial abnormalities and increased endoplasmic reticulum stress is shown. 5 all this oxidative and nitrosative factors stress is a particular focus. 3 Currently on cisplatin against toxic effects an approved treatment that can be used protocol and a specific antidote not found8, still heavily anti-toxicity strategies is being investigated. In its pathogenesis, oxidative and nitrosative stress Considering the benefits of using antioxidants lays out. Therefore, in this study, with cisplatin of cardiotoxicity used for years in the clinic for the prevention of serious side effects even at high doses NAC 9, a powerful antioxidant effectiveness has been studied. Method Erciyes University Scientific by the Research Projects Commission supported (Project no: TTU-2015-6134) and Erciyes University Faculty of Medicine Ethics Approved by the Board (dated 10/12/2014, decision no:14/168) this study is in Erciyes It was held at the University. During the study, 12 hours on a light/dark cycle, normal room rats kept at temperature (22±1ºC) and humidity, with standard pellet feed and tap water fed. To adapt to the environment for the purpose of; rats, at least before starting the study It was taken into the same experimental environment a week ago. The study included eight rats each. four groups were created: Control (KONT), cisplatin (CP), NAC-250 and CP+ NAC group. Cisplatin10 and Literature information and preliminary data on NAC11 doses study results (data not shown) decided in the light of The first application to the control group saline twice a day, four hours apart (SF) injection was given and two consecutive days It was continued with a single dose of SF. to the CP group at a dose of 10 mg/kg rat weight on the first day cisplatin (Cisplatin DBL®, 100 mg/ 100 mL) while the other injection Only SF application was made at the time. 250 mg/kg for three days in NAC-250 group rat weight NAC (Asist®, Bilim Pharmaceuticals 300 mg/ 3 mL, 10%) was applied. To the CP+NAC group on the first day of the study, first a single dose of 10 mg/kg rat weight dose of cisplatin; two agents cisplatin to minimize its interaction at the fourth hour of its application12 and 250 mg/kg rat weight for two more consecutive days dose of NAC was applied